Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?

por Hauschild, A.
Publicado 2009

Epidemiology of invasive cutaneous melanoma

por MacKie, R. M., Hauschild, A., Eggermont, A. M. M.
Publicado 2009

Staging of cutaneous melanoma

por Mohr, P., Eggermont, A. M. M., Hauschild, A., Buzaid, A.
Publicado 2009

Two different approaches for pharmacokinetic modeling of exhaled drug concentrations

por Kreuer, S., Hauschild, A., Fink, T., Baumbach, J. I., Maddula, S., Volk, Th.
Publicado 2014

Surgery and radiotherapy in the treatment of cutaneous melanoma

por Testori, A., Rutkowski, P., Marsden, J., Bastholt, L., Chiarion-Sileni, V., Hauschild, A., Eggermont, A. M. M.
Publicado 2009

Biomarkers in melanoma

por Gogas, H., Eggermont, A. M. M., Hauschild, A., Hersey, P., Mohr, P., Schadendorf, D., Spatz, A., Dummer, R.
Publicado 2009

Utility of adjuvant systemic therapy in melanoma

por Eggermont, A. M. M., Testori, A., Marsden, J., Hersey, P., Quirt, I., Petrella, T., Gogas, H., MacKie, R. M., Hauschild, A.
Publicado 2009

Immunotherapy of distant metastatic disease

por Schadendorf, D., Algarra, S. M., Bastholt, L., Cinat, G., Dreno, B., Eggermont, A. M. M., Espinosa, E., Guo, J., Hauschild, A., Petrella, T., Schachter, J., Hersey, P.
Publicado 2009

Small molecules and targeted therapies in distant metastatic disease

por Hersey, P., Bastholt, L., Chiarion-Sileni, V., Cinat, G., Dummer, R., Eggermont, A. M. M., Espinosa, E., Hauschild, A., Quirt, I., Robert, C., Schadendorf, D.
Publicado 2009

Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)

por Hauschild, A, Garbe, C, Stolz, W, Ellwanger, U, Seiter, S, Dummer, R, Ugurel, S, Sebastian, G, Nashan, D, Linse, R, Achtelik, W, Mohr, P, Kaufmann, R, Fey, M, Ulrich, J, Tilgen, W
Publicado 2001

Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety

por Malvehy, J, Hauschild, A, Curiel-Lewandrowski, C, Mohr, P, Hofmann-Wellenhof, R, Motley, R, Berking, C, Grossman, D, Paoli, J, Loquai, C, Olah, J, Reinhold, U, Wenger, H, Dirschka, T, Davis, S, Henderson, C, Rabinovitz, H, Welzel, J, Schadendorf, D, Birgersson, U
Publicado 2014

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial

por Guo, J., Carvajal, R. D., Dummer, R., Hauschild, A., Daud, A., Bastian, B. C., Markovic, S. N., Queirolo, P., Arance, A., Berking, C., Camargo, V., Herchenhorn, D., Petrella, T. M., Schadendorf, D., Sharfman, W., Testori, A., Novick, S., Hertle, S., Nourry, C., Chen, Q., Hodi, F. S.
Publicado 2017

Vemurafenib in patients with BRAF(V600) mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

por Chapman, P B, Robert, C, Larkin, J, Haanen, J B, Ribas, A, Hogg, D, Hamid, O, Ascierto, P A, Testori, A, Lorigan, P C, Dummer, R, Sosman, J A, Flaherty, K T, Chang, I, Coleman, S, Caro, I, Hauschild, A, McArthur, G A
Publicado 2017

Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)

por Saiag, P., Gutzmer, R., Ascierto, P. A., Maio, M., Grob, J.-J., Murawa, P., Dreno, B., Ross, M., Weber, J., Hauschild, A., Rutkowski, P., Testori, A., Levchenko, E., Enk, A., Misery, L., Vanden Abeele, C., Vojtek, I., Peeters, O., Brichard, V. G., Therasse, P.
Publicado 2016

Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study

por Gutzmer, R, Rivoltini, L, Levchenko, E, Testori, A, Utikal, J, Ascierto, P A, Demidov, L, Grob, J J, Ridolfi, R, Schadendorf, D, Queirolo, P, Santoro, A, Loquai, C, Dreno, B, Hauschild, A, Schultz, E, Lesimple, T P, Vanhoutte, N, Salaun, B, Gillet, M, Jarnjak, S, De Sousa Alves, P M, Louahed, J, Brichard, V G, Lehmann, F F
Publicado 2016

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

por Long, G. V., Flaherty, K. T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalà, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J. B. A. G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M. A., Lane, S. R., Legos, J. J., Mookerjee, B., Grob, J.-J.
Publicado 2017

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

por Long, G V, Flaherty, K T, Stroyakovskiy, D, Gogas, H, Levchenko, E, de Braud, F, Larkin, J, Garbe, C, Jouary, T, Hauschild, A, Chiarion-Sileni, V, Lebbe, C, Mandalá, M, Millward, M, Arance, A, Bondarenko, I, Haanen, J B A G, Hansson, J, Utikal, J, Ferraresi, V, Mohr, P, Probachai, V, Schadendorf, D, Nathan, P, Robert, C, Ribas, A, Davies, M A, Lane, S R, Legos, J J, Mookerjee, B, Grob, J -J
Publicado 2019